Dr. Scott Rocklage has been the Managing Partner at 5AM Ventures since 2004. Before he joined the company, Dr. Rocklage had a wealthy background in health management sector that spanned for three decades.
He has worked in various organizations involved in healthcare management including Nycomed, Catalytica, Cubist Pharmaceuticals, and Salutar. Under his strategic leadership, the company has developed new drug applications for Teslascan, Cubicin, and Omniscan.
Before joining 5AM Ventures, Dr. Scott Rocklage worked as the Chairman and Chief Executive Officer of the Cubist Pharmaceuticals. He also worked as the President and Chief Executive Officer of the Nycomed Salutar. At Catalytica and Salutar, he held various research as well as development positions.
Dr. Scott Rocklage’s educational background is impressive. To this end, he graduated from America’s famous and prestigious University. These are the University of California in Berkeley as well as the Massachusetts Institute of Technology. In this case, he graduated with a Bachelor’s of Science in Chemistry from the former and a Ph. D in chemistry from the former.
He was also lucky and honored to have conducted his Ph. D research work at the Richard R. Schorock’s Laboratory. The lab is run by a renown scientist Richard Schrock who was awarded the 2005 Nobel Prize in Chemistry for his contribution to Chemistry.
Dr. Rocklage achievements include being an inventor of more than 30 American patent. Additionally, he has authored and published over a hundred research papers in peer-reviewed journals.
In addition to his role at 5AM Ventures, Dr. Scott Rocklage holds other important positions in other organizations. One of these roles includes at Cidara, Rennovia, and Kinestral organizations where he serves as the Chairman of the Board. Read more: Scott Racklage | Bloomberg
Asked what makes his a successful professional in healthcare management, he noted that he has a high regard to calendaring, prioritization and time management.
He advises young scientists to work with other entrepreneurs who are critical when developing medicines which treat the unmet medical needs. Additionally, he notes that targeting specific genotypes of mutations is a trend that should interest young scientists as it holds key to developing and improving medicines which will save more lives in the future.
Currently, Dr. Rocklage resides in Boston at 5AM Ventures Offices. He sits at the Whitehead Institute as a Board of Associates member. This institute is considered as prestigious non-profit research and educational institution that deals with biomedical research.
For his outstanding achievements, Dr. Scott Rockalage is considered as among the most influential professionals in healthcare management in the United States.
Learn more about Scott Rocklage: